Steve Baxter

you talked about the potential clawback on the tariffs. How do you account for that?

I'm trying to understand whether you're suggesting that the benefits from lapping deals and ramping synergies

Just wanted to see if you might be willing to size the cumulative impact of the Pharma items that you called out in the quarter. I think your commentary was potentially above the midpoint of the ra...

for China, is this the full 145%? I guess for the rest of the world, is it the current 10%

Do we think about this as largely just being the Q1 underlying favorability in the business

I was hoping you could maybe expand a little bit more on the health care medical membership outlook that you gave

the net payable for risk adjustment is up by, I think, over $300 million sequentially versus year-end

I wanted to come back to the the Medicaid moving pieces. I guess I just love a little bit better of a sense of maybe how much incremental decline in membership

does Florida actually improve sequentially in the fourth quarter now

Is there anything structurally different about the dislocation in the rest of the book that suggests that a lower rate update would really be kind of the sensible base case

I was hoping you could perhaps break that into perhaps the contribution from OneOncology, whether we should think about any kind of transitory costs

I was hoping that you could better help us understand the acceleration in U.S. Healthcare earnings growth. I believe it was 23% last quarter to more like 29% this quarter

I was hoping you might be willing to give us an update on what the guidance revision for the U.S. business would have been on an organic basis

have you actually made any changes to how you're booking current year cost trend into the P&L

Wondering if there's an equivalent amount, if you think about kind of excluding the items that you called out

Just wanted to check in on the group MA margins. I was wondering where this PDR places margins for the business in 2025

just trying to understand better what are these prior period revenue adjustments that you’re talking about. What business do those actually relate to

where the Medicare Advantage margins ended the full year 2024, and what’s assumed in the guidance for 2025

it seems like you're seeing some level of moderation in Medicare and are confident enough at this stage to identify that

I think you're talking about potentially several hundred million dollars of investments. Obviously, the company is investing every year. So trying to understand what you guys are trying to spike th...

I was hoping if you could expand a little bit, maybe quantitatively, on kind of how different the effectuation rate is actually coming in

I was hoping maybe, Mark, if you could also just elaborate on Health Benefits and whether those margin targets are still intact for '27 or have evolved

the only sort of year-over-year number you haven't given us yet is on resiliency

Could you expand a little bit on the pause Texas Medicaid supplemental payment that was mentioned during the guidance color

The 5.4% you gave on the managed care volumes. Just to make sure that that's inclusive of the exchanges or excluding it?

the Medicaid supplemental benefit on a full year basis is now, I think, $200 million larger than what you discussed on the third quarter call

how much of a benefit you think you might have seen from flu and weather in the quarter

could you expand a little bit on the level of earnings that you can drive purely outside of the MA underwriting?

would love if you could give some initial thoughts on the type of margin that you'll assume for the new to Humana sales growth

I was hoping you could speak to what you saw in terms of inpatient utilization trends in Medicare Advantage during the second quarter

could you walk us through your visibility on risk adjustment at this point in year and whether that needs to be thought about differently

is that included in the $51 million that you sized? Or is that something that's incremental

there could be some upward pressure on the uninsured rate going into 2026 coming from the individual market

the SG&A decline pretty substantially year-over-year, wondering if you could comment a little bit on the efficiencies

are there things that you think we should be thinking as a potential maybe adjustments to the baseline

does that really just reflect the kind of the changes directly on the incremental staffing side? Are you thinking that there could be any spillover impact to your base wage structure

just hoping you could elaborate more on the change in surgical you saw in the quarter going from down slightly as of last quarter to up slightly this quarter. I guess where are you seeing that impr...

how should we think about a world where maybe that is a more fixed stream going forward, your ability as a company to still kind of deliver the type of same-store revenue and adjusted EBITDA growth...

sizing the full year amount that the medical malpractice expense came in above your initial plan and and how much of that you assume normalizes

I would love to hear if you could discuss your confidence level in further margin recovery for 2027

have you indicated that you'd participate in the BALANCE program for GLP-1s?

was hoping you could speak to oneone rates that you're seeing and maybe contrast that to the rates you were seeing in 2025?

Can you help us think about the breakout between individual duals and group?

what were the old value-based care target margins to compare the five percent to?

Could you talk about where MA margins are now expected to shake out inside your 2025 guidance?

I was wondering if you had any early perspective to share on the Medicare Advantage advance notice for 2026